Archive by Author

Hot Investor Mandate: Family Office Invests in Life Science Companies, Preferring to Invest in Therapeutics Companies Based in Europe With Global Outlook

19 Oct

A family office investment firm is focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.

The firm looks to invest 70% in Therapeutics, 10% in Medical Devices, 10% Digital Health and 10% in Diagnostics. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.

The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ salescore@lifesciencenation.com.

Hot Investor Mandate: Firm Backed By Multiple Health Systems Seeks to Fund Medtech, Digital Health, and Healthcare Services Companies in the USA

19 Oct

A strategic healthcare venture investment representing multiple health systems as LPs has decades of investment experience. The firm makes equity investments into early- to late-stage companies with additional capital reserved for follow on financings. The firm prefers to invest in USA-based companies.

The firm is currently looking for new opportunities in the Medical Device, Diagnostic, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on device companies in the pre-commercial stage. The firm has a preference for platform technologies and companies whose products are already commercialized. The firm’s Healthcare IT and Healthcare Services investments are typically in the commercial or growth stages. The firm invests in privately held healthcare companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers. The firm typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ salescore@lifesciencenation.com.

Hot Investor Mandate: Europe-Based VC Invests Up to €25M in Biotech, Medtech, and Enabling Tech Companies, Opportunistic in Specific Areas of Interest

19 Oct

A firm with multiple offices throughout Western Europe makes biotech and medtech investments from an evergreen fund. The firm typically makes initial investments of EUR 7-15M at the Series A or B stage, and may commit EUR 25M over the life of an investment. The firm invests mainly across Europe, and aims to make at least 4 life science investments per year, with 80% in the therapeutics space.

The firm invests across the biotech and medtech sectors. Within the biotech sector, the firm prefers to invest in platform technologies, multi asset and single asset companies, and will invest as early as the preclinical stage. The firm will consider any therapeutic area, and has an interest in orphan drugs. The firm prefers opportunities that do not require very large clinical trials. For medical devices, the firm prefers to invest in companies with products with a global potential, that are close to acquiring a CE Mark and/or US approval and that are preparing commercialization. The firm is also interested in enabling technologies such as next-gen PCR and lab equipment. The firm does not invest in company-creation opportunities: the firm prefers to work with companies that already have high-quality management teams that have proven themselves through past success in the life science industry, and who have a strong network within the industry. The firm also considers the company’s capital efficiency, future capital needs, and the strength of the company’s prior investment syndicate. The firm prefers to lead or co-lead investments, and is a highly active investor at a portfolio company’s board level.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ salescore@lifesciencenation.com.

Hot Investor Mandate: VC With USA Operations Invests $1-5M in Companies in the Intersection of Biology and Technology, Including Synthetic Biology

19 Oct

A venture capital firm headquartered in the US is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.Ā  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ salescore@lifesciencenation.com.

Life Science Nation Will Assess and Help Determine How Prepared You Are to Fundraise

12 Oct

ByĀ Caitlin Dolegowski, Marketing Manager, LSN

Life Science Nation (LSN) prepares early-stage entrepreneurs for their Global Roadshow Campaign. This begins with determining where you are in the preparation and execution process. LSN specializes in the process of launching your fundraising campaign.

Are you prepared to launch?

Do you have your unique and compelling story down?
Successful entrepreneurs are always the best storytellers. LSN can help determine if you do, we can offer suggestions and education on developing a compelling narrative.

Watch LSN Webinar – It All Starts with The Story

Is your story supported by a strong elevator pitch, pitch deck and executive summary?Ā 
LSN provides templates and formats to prepare for potential investors. Click logos below to see examples.

What does your current partner and investor target list look like?Ā 
LSN can ignite and create a better global target list. The LSN Investor Database covers over 10 types of investors including:
  • Angel Groups
  • Corporate Venture Capital
  • Endowments/Foundations
  • Family Office/Private Wealth Funds
  • Government Organizations
  • Hedge Funds
  • Institutional Alternative Investors
  • Large Pharma/ Biotech Companies
  • Private Equity
  • Venture Capital
Companies can cast a wide net, looking at all types of investors and assessing which would be the best partner moving forward. When evaluating investors, companies can download or export search results and set up email alerts, taking advantage of the constantly updated new profiles as LSN continues to curate the database…Learn More
Do you have a CRM to organize and manage the process?
It is impossible to manage 600-800 accounts in a spreadsheet. The LSN investor database can be integrated into Salesforce…Learn More
Do you have the right staff person that is assigned to setting up meetings?
This is where 99% of the startups fail. They have no designated part-time or full-time staff dedicated to setting up meetings for the CEO and then monitoring and documenting how the meeting went and what the deliverables and next steps are. This is a crucial but overlooked aspect of fundraising and why most attempts fail. RAISING MONEY IS A NUMBERS GAME. Having a dedicated staff person who can do the canvassing, tracking, and follow-up is how the game is played.
Do you have meaningful conferences scheduled and accounted for on your calendar? Remember the NUMBERS GAME?
LSN hosts The Redefining Early Stage Investments (RESI) conference series that connects start-ups to early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics, and digital health (4 Ds). RESI caters to both the earliest-stage start-ups, those seeking grants, seed, and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare…Learn More
RESI Conference Logo

Visit RESI Website:
RESIConference.com

At Life Science Nation we have a dedicated research team that meets regularly with early-stage investors. The LSN team has a keen understanding of what investors and strategic partners are looking for and we specialize in working with startups and plugging them into the LSN platform and aiding in their global fundraising and partnering initiatives. Let us take you through this step-by-step process and see where you are and how we can prepare you for success.

Read This: 7 Startups, 7 Unicorns, and $7M of a $37M Round Raised at RESIAn interview with Thomas Farb-Horch, CEO, Thrive Bioscience

LSN Heading to Hong Kong & Singapore: Rising Healthcare and Life Science Hotspots in Asia

12 Oct

ByĀ Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

The LSN team will be collaborating with Hong Kong Science and Technology Park (HKSTP) on October 19-20 and Life Science Incubator (Singapore) on October 29 to deliver the LSN Entrepreneurial Education boot camp to fundraising CEOs and scientist-entrepreneurs, aiming to help kick start their fundraising campaign and business developments on a truly global scale, and enhance LSN’s presence in the Asia Pacific region.

In recent years, the global healthcare and life science industries have undergone a remarkable transformation, characterized by increased capital inflow, soaring investment activities and groundbreaking innovations. Asia emerged as the epicenter of this moving landscape and Hong Kong and Singapore have solidified their positions as innovation hubs that offered unique advantages for fostering life science and healthcare innovation ecosystems. Their strategic locations, favorable government policies & promotions, and robust infrastructures make them the preferred destinations for early-stage life science and healthcare innovators who are looking to make an impact in one of the largest and most rapidly evolving life science markets, the Asia Pacific region, estimated to be USD 7.21 billion as of 2023.

Here are some recent highlights on Hong Kong and Singapore’s innovation ecosystems:

Geographic Advantage: Collaboration with China’s GBA

The strategic geographical location of both Hong Kong and Singapore are an invaluable asset for their life science and healthcare innovation ecosystem. Hong Kong, located on the southern coast of Mainland China, is a bridge to the Guangdong-Hong Kong-Macao Great Bay Area (GBA), which comprises several fastest-developed, major cities of Mainland China. Notably, there has been a surge in collaborations aimed at promoting tech and life science innovations between the governments, with a new science park established on the Hong Kong-ShenZhen border. In 2023, special measures were placed for medical devices and drugs that were approved in Hong Kong. This geographic position presents unparalleled opportunities for cross-border collations and access to the vast Chinese market.

R&D Powerhouse and Elite Research Facilities

Both Hong Kong and Singapore have made substantial efforts in fostering a conducive environment for research and development. With over 50 national and international research facilities, state-of-the-art laboratories and top-ranked universities, there is no lack of scientific talent and research capacities in HK and Singapore.

From 2021-2023, both Hong Kong and Singapore have set up partnerships with leading global pharmaceutical companies, such as Johnson & Johnson, Roche and AstraZeneca, to promote healthcare innovations and co-incubate early-stage projects.

Government Supports

In addition to research facilities, the government policies in both regions are designed to promote life science and healthcare innovations. These include grants, tax incentives and various financial support schemes. Prominent government initiatives such as Singapore’s Agency for Science, Technology, and Research (A*STAR) and Hong Kong’s Research Grants Council (RGC) actively support scientific research and innovation.

LSN believes a global ecosystem with strong interconnections and cross border collaborations will benefit both investors and entrepreneurs from around the globe, driving healthcare and life science forward with quality projects being properly funded despite their locations. Below are information and registration links for the two Boot Camps. I hope you can join us and we look forward to meeting healthcare & life science innovators in Hong Kong and Singapore.

HKSTP Bootcamp (1)

LSI-LSN Programme Flyer with QR Code (002)

Life Science Nation and California Life Science Join Force Again in RESI JPM 2024

12 Oct

ByĀ Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) proudly announces that California Life Sciences (CLS) will serve as a title sponsor for RESI JPM again. RESI JPM is LSN’s flagship conference taking place January 9-11, 2024, at Marines’ Memorial Club & Hotel, San Francisco, during JP Morgan Healthcare week.

Earlier this year, during RESI JPM 2023, CLS not only brought many their members to participate in RESI but also featured 8 early-stage life science startups across the biotech and medtech sectors in the RESI Innovator’s Pitch Challenge (IPC) as part of the CLS Innovation Track. This section successfully connected these outstanding life science innovators with LSN’s global investors and partners.

CLS interview

Read: Interview with Shikha Sharma, Senior Director, Innovation at California Life SciencesĀ (CLS)

RESI JPM 2024 will see over 500 investors and licensing partners and 500 fundraising executives congregate during JPM week, CLS will bring their members who are early-stage life science startups to participate in RESI JPM which will serve to further the visibility and growth of these fundraising firms with LSN’s global partner network. With this excellent event for collaboration, CLS will bring into the spotlight many of the elite technology assets emerging from the state’s most impactful life sciences trade association. As part of CLS’s portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid CLS members in their fundraising journeys. Importantly, opportunities like RESI connect them with Seed and Series B investors, channels, and licensing partners.

CLS is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.

RESI-SF-2024-Banner-1100